Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Both can be effective in weight loss, but in head-to-head trials, tirzepatide has a slight edge over semaglutide
Oncogene 40 , 39743988 (2021)
Itching at injection site Mild itching around the injection site is relatively common with GLP-1 receptor agonists
Clinical studies suggest Tirzepatide produces greater average weight loss than Semaglutide due to its dual receptor activity, though both are highly effective
the Employee Retirement Income Security Act of 1974 (ERISA)
Doctors who Science News talked to for this story emphasized the significance of the recent MASH progress, calling this era in the field a watershed moment, and the more than a dozen new medications in development a tidal wave. Rezdiffra may have been the first drug FDA-approved for MASH, but in the next two to three years, Su says, there will be many more
